Estrus response and fertility after a single cloprostenol treatment in dairy cows with various ovarian structures.

The objective of this study was to determine rates of estrus and conception in lactating multiparous Holstein cows given 500 μg of cloprostenol intramuscularly after detection of the following ≥ 60 d after parturition: a solid corpus luteum (CL), a CL with a nonechodense cavity ≤ 20 mm in diameter (CLcav), a luteal cyst (cavity > 20 mm in diameter and a luteinized wall > 3 mm in diameter), or a follicular cyst (cavity > 20 mm and a luteinized wall ≤ 3 mm in diameter). The estrus rates were 335/419 (80.0%), 183/223 (82.

Effect of perinatal synthetic steroid hormone (allylestrenol, diethylstilbestrol) treatment (hormonal imprinting) on the bone mineralization of the adult male and female rat.

Neonatal treatment with allylestrenol or diethylstilbestrol (DES) reduced the bone mineral content (BMC/bw) of the adult (four months old) female rats, without influencing bone mineral density (BMD/bw). In males these neonatal treatments elevated BMC and BMD alike. Ovariectomy alone decreased BMC and BMD alike; however the neonatal hormone treatments did not influence this reduced value.

Effect of neonatal glucocorticoid treatment on bone mineralization of adult nontreated, dexamethasone-treated or vitamin D3-treated rats.

1. Single neonatal dexamethasone (DEX) treatment significantly decreased the body weights of 5-month old male rats. There was no significant difference in females.

Effect of single neonatal vitamin D3 treatment (hormonal imprinting) on the bone mineralization of adult non-treated and dexamethasone treated rats.

Hormonal imprinting (the first encounter between the hormone and receptor after birth) is needed for the normal development of receptor. Presence of the appropriate hormone in excess, or its absence, as well as presence of hormone-like molecules able to bind to the maturing receptor in this time, can cause faulty imprinting. In this experiment the effect of neonatal treatment with a single dose of 0.

Dehydroepiandrosterone sulphate and bone mineral density.

Several series of data suggest that alterations in adrenal androgen output might be a contributing factor to changes in bone mass. To study the possible relationship between bone density and serum levels of dehydroepiandrosterone sulphate (DHEAS) we investigated 105 women (aged 45-69 years; 76 postmenopausal, 29 perimenopausal). The patients were divided into two groups according to the bone mineral density (BMD) measurement (normal density n = 50, low density n = 55).

[Changes in osteocalcin serum levels in children with growth hormone deficiency during substitution therapy].

Unlabelled: Osteocalcin (OC), a specific marker of osteoblast activity, was measured in 21 short, growth hormone deficient (GHD) children before and during 2 years of growth hormone (GH) therapy. Anthropometric and serum measurements were performed in every three-month during the first year (15 patients) and after the second year (16 patients). Mean OC concentration was significantly lower in GHD children compared to normal value (11.

[Zinc excretion in osteoporotic women].

Urinary zinc excretion was detected in 24 normal and 25 age matched osteoporotic women. The osteoporotic group was classified in two groups on the basis of bone mineral density (BMD) measurements. Urinary zinc excretion was 327 micrograms/g creat.

[Treatment of postmenopausal osteoporosis with low doses of calcitonin and a calcitonin-anabolic combination].

Menopausal osteoporotic women (age: 49-69, mean: 59.5 years) with crush fractures of the spine were treated with low doses of calcitonin (Miacalcic, 350 U/month), or with calcitonin + anabolic steroid (Retabolil, 50 mg/month). Efficacy of the therapy was controlled by single foton absorptiometry of midshaft and distal radius, by X-ray morphometry and by registering new crush fractures of the spine.

[Spinal and appendicular osteoporosis in streak gonad syndrome. Photon absorptiometric and roentgen-morphometric studies].

Patterns of bone loss in the axial and the appendicular skeleton were studied in 48 women with streak gonad syndrome (age: between 14-38 years, mean: 25.5 years). Bone mineral content was measured in vivo at the lumbar spine and right femoral neck by dual photon absorptiometry and at the midradius and distal radius by single photon absorptiometry.

Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine.

Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin+calcium therapy.

[Mean value of bone mineral content in Hungary measured by dual-photon absorptiometry].

Bone mineral content and density of the lumbar spine and femoral neck was measured by dual energy X-ray absorptiometry in normal volunteers (89 women, 77 men) in different age groups. Peak values in both sexes occurred in the 3rd decade and are about 25% higher in men than those in women. In women the bone loss begins around 40 years at lumbar spine and also at the femoral neck.

[Decreased serum osteocalcin level in non-alcoholic and alcoholic chronic liver diseases].

Serum level of osteocalcin (OC) is believed to be a specific biochemical parameter of bone formation. Decreased serum OC has been reported in alcohol-intoxicated subjects, in patients with primary biliary cirrhosis and in patients with chronic alcoholic liver disease. The question was, whether lower OC level could be detected in patients with nonalcoholic and non-cholestatic chronic liver disease.

Serum bone Gla protein in streak gonad syndrome.

Osteoporosis is one of the most common complications of streak gonad syndrome (SGS), however its pathogenesis is still unclear. Bone Gla protein (BGP) has been found to be a serum marker of bone turnover in various metabolic disease states. In the present study serum BGP and alkaline phosphatase (AP) were measured in 13 osteoporotic patients with SGS and in 56 healthy women.

[Proposal for the management of primary care for patients with suspected osteoporosis and patients with actual osteoporosis within the framework of the Hungarian health care system].

The author at first gives the definition of various facts which are important in the concept of metabolic bone disease from the point of view of direct practice. Then he summarizes the clinical signs of severe or mild osteoporosis, as well as the factors, suggesting osteoporosis in a certain patient. The objective methods, used in the diagnosis of calcipenic osteopathy are also reviewed from the simple X-ray films to the various osteodensitometric methods.

Androgens and bone mineral content in patients with subtotal thyroidectomy for benign nodular disease.

To investigate the influence of thyroid surgery on the skeleton and different hormones a well characterized patient group of 24 women was selected who had undergone subtotal thyroidectomy for euthyroid benign nodular disease and remained euthyroid after the operation. Bone mineral content was determined in lumbar vertebrae, femoral neck and radius by dual and single photon absorptiometry. The serum levels of calcitonin, dehydroepiandrosterone, dehydroepiandrosterone-sulphate, androstenedione, total testosterone, cortisol and 25-hydroxyvitamin D were measured.

Calcitonin secretion in streak gonad syndrome (Turner's syndrome).

Osteoporosis in one of the most common complications of streak gonad syndrome (SGS), however, its pathogenesis is still unclear. To test whether SGS is associated with calcitonin (CT) deficiency, 11 affected individuals and 8 age-matched healthy women were studied. Calcium, 3.